Novel HSD17B13 Inhibitors for Treating Liver Diseases
Overview
Overview
Journal
ACS Med Chem Lett
Publisher
American Chemical Society
Specialty
Chemistry
Date
2024 Jun 19
PMID
38894932
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Provided herein are novel HSD17B13 inhibitors, pharmaceutical compositions, use of such compounds in treating liver diseases, and processes for preparing such compounds.
References
1.
Tian Y, Wang B
. Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies. J Gastroenterol Hepatol. 2023; 38(11):1877-1885.
PMC: 10693931.
DOI: 10.1111/jgh.16330.
View
2.
Wang M, Peng Z
. 17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease. Pharmacol Ther. 2023; 246:108428.
DOI: 10.1016/j.pharmthera.2023.108428.
View
3.
Montero-Vallejo R, Maya-Miles D, Ampuero J, Martin F, Romero-Gomez M, Gallego-Duran R
. Novel insights into metabolic-associated steatotic liver disease preclinical models. Liver Int. 2024; 44(3):644-662.
DOI: 10.1111/liv.15830.
View
4.
Jokinen M, Luukkonen P
. Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease. Trends Pharmacol Sci. 2024; 45(4):319-334.
DOI: 10.1016/j.tips.2024.02.003.
View
5.
Hernandez-Evole H, Jimenez-Esquivel N, Pose E, Bataller R
. Alcohol-associated liver disease: Epidemiology and management. Ann Hepatol. 2023; 29(1):101162.
DOI: 10.1016/j.aohep.2023.101162.
View